Skip to content
My WebMD Sign In, Sign Up

Pancreatic Cancer Health Center

Font Size

2 Drugs Look Promising for Rare Pancreatic Cancer

Targeted Treatment Slowed Disease Progression in Studies

The Sutent/Afinitor Studies continued...

After 18 months, 34% of the Afinitor-treated patients showed no evidence of disease progression, compared to just 9% of the placebo-treated patients.

Although both drugs were clearly effective, a significant number of patients reported troubling side effects, including a drop in infection-fighting white blood cells in 12% of those who took Sutent.

Yao says canker sores were the most commonly reported side effect in the Afinitor trial, with 64% of patients developing the sores at some point in treatment and 7% developing sores severe enough to cause problems eating and drinking.

In an editorial published with the studies, Robert T. Jensen, MD, of the NIH’s Digestive Disease Branch and Gianfranco Delle Fave, MD, of Italy’s University La Sapienza, write that it remains to be seen how the side effect profiles of the drugs will affect patient adherence.

“Drug-related side effects...are particularly important to consider, given that treatment will be long term and that many patients have an excellent quality of life with no treatment until late in the disease course, even with advanced disease that is progressive,” they write.

Data from both the studies, which were funded by the drugs’ manufacturers, were presented last summer at the 12th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

1|2

Today on WebMD

Pancreatic Cancer Symptoms And Treatment
SLIDESHOW
what is your cancer risk
HEALTH CHECK
 
cancer fighting foods
SLIDESHOW
Pancreatic Cancer Diagnosis And Early Detection
REFERENCE
 
Integrative Medicine Cancer Quiz
QUIZ
Patrick Swayzes Widow Healing From Loss
FEATURE
 
Pets Improve Your Health
SLIDESHOW
Resolved To Quit Smoking
SLIDESHOW
 

WebMD Special Sections